Galapagos NV - Product Pipeline Review - 2014

Published: Jun, 2014 | Pages: 53 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)

Galapagos NV - Product Pipeline Review - 2014

Summary

Global Markets Direct's, 'Galapagos NV - Product Pipeline Review - 2014', provides an overview of the Galapagos NV's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galapagos NV's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Galapagos NV including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galapagos NV's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Galapagos NV's pipeline products

Reasons to buy

- Evaluate Galapagos NV's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galapagos NV in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galapagos NV's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galapagos NV and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galapagos NV
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Galapagos NV and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Galapagos NV Snapshot 6
Galapagos NV Overview 6
Key Information 6
Key Facts 6
Galapagos NV - Research and Development Overview 7
Key Therapeutic Areas 7
Galapagos NV - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Out-Licensed Products 12
Out-Licensed Products/Combination Treatment Modalities 13
Galapagos NV - Pipeline Products Glance 14
Galapagos NV - Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Galapagos NV - Early Stage Pipeline Products 16
Preclinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Galapagos NV - Drug Profiles 18
GLPG-0634 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
GLPG-0974 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
GLPG-0492 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GLPG-1205 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GLPG-1179 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
GLPG-1492 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
GLPG-1577 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
GLPG-1690 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GLPG-1790 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
GLPG-1837 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Monoclonal Antibodies for Bone and Joint disease 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Drugs for Cancer 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drugs for Cystic Fibrosis and COPD 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Drugs for Osteoporosis 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Small Molecules for Cancer 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
Small Molecules for Metabolic, Cardiovascular and Inflammatory Disease 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Galapagos NV - Pipeline Analysis 36
Galapagos NV - Pipeline Products by Target 36
Galapagos NV - Pipeline Products by Route of Administration 38
Galapagos NV - Pipeline Products by Molecule Type 39
Galapagos NV - Pipeline Products by Mechanism of Action 40
Galapagos NV - Recent Pipeline Updates 42
Galapagos NV - Dormant Projects 49
Galapagos NV - Discontinued Pipeline Products 50
Discontinued Pipeline Product Profiles 50
GLPG-0187 50
GLPG-0259 50
GLPG-0492 50
GLPG-1332 50
Small Molecules for Osteoarthritis 50
Galapagos NV - Locations And Subsidiaries 51
Head Office 51
Other Locations & Subsidiaries 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 53
Disclaimer 53

List of Tables
Galapagos NV, Key Information 6
Galapagos NV, Key Facts 6
Galapagos NV - Pipeline by Indication, 2014 8
Galapagos NV - Pipeline by Stage of Development, 2014 10
Galapagos NV - Monotherapy Products in Pipeline, 2014 11
Galapagos NV - Out-Licensed Products in Pipeline, 2014 12
Galapagos NV - Out-Licensed Products/ Combination Treatment Modalities, 2014 13
Galapagos NV - Phase II, 2014 14
Galapagos NV - Phase I, 2014 15
Galapagos NV - Preclinical, 2014 16
Galapagos NV - Discovery, 2014 17
Galapagos NV - Pipeline by Target, 2014 37
Galapagos NV - Pipeline by Route of Administration, 2014 38
Galapagos NV - Pipeline by Molecule Type, 2014 39
Galapagos NV - Pipeline Products by Mechanism of Action, 2014 41
Galapagos NV - Recent Pipeline Updates, 2014 42
Galapagos NV - Dormant Developmental Projects,2014 49
Galapagos NV - Discontinued Pipeline Products, 2014 50
Galapagos NV, Subsidiaries 51